Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
Park Therapeutics is a private company that was formed to address the desperate need for better and safer analgesics. We recently acquired rights to PRK-101 which was discovered and originally developed by a pharma for strategic reasons. It is a PIII-ready NCE with a novel MOA that been extensively studied in a global development program of nearly 2,000 patients so has been significantly de-risked. It has already been shown to be effective in a wide range of indications and safer than existing alternatives, especially in terms of abuse and addiction potential. Park intends to develop PRK-101 for chronic lower back pain (cLBP), peripheral neuropathic pain and other chronic pain indications and plans to initiate PIII studies in 2021. We are currently seeking Series A funding, ex-US partnerships and additional clinical-stage pain programs to add to our pipeline.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Park_20Therapeutics_acfed937.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
PRK-101
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![photo](/sites/default/files/hubb_images/2996/photos/user1.Hackworth.ed39c707.jpg)
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved